Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. A Cancer J Clinic 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Eliaa SG, Al-Karmalawy AA, Saleh RM, Elshal MF. Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mtor pathway and inhibition of calmodulin: in vitro and molecular docking studies. ACS Pharmacol Transl Sci 2020;3:1330–8.
   PubMedGoogle Scholar
• Khattab M, Al‐Karmalawy AA. Revisiting activity of some nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations. Front Chem 2021;9:628398.
   PubMed Web of Science ®Google Scholar
• Al-Karmalawy AA, Khattab MJNJOC. Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor. N J Chem 2020;44:13990–6.
   Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Nocentini A, et al. Novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene)thiazolidin-2-ylidene)amino) benzenesulfonamides: synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies. Eur J Med Chem. 2017;139:250–62.
   PubMed Web of Science ®Google Scholar
• Eissa IH, El-Helby A-GA, Mahdy HA, et al. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: design, synthesis, and anti-proliferative evaluation. Bioorg Chem. 2020;105:104380.
   PubMed Web of Science ®Google Scholar
• Eissa IH, Ibrahim MK, Metwaly AM, et al. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Bioorg Chem 2021;107:104532.
   PubMed Web of Science ®Google Scholar
• Ran F, Li W, Qin Y, et al. Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: design, synthesis, and biological evaluation. Oxidat Med Cell Long 2021;2021:8321400.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Al-Wabli RI, Almutairi MS, et al. Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents. J Enzyme Inhib Med Chem 2018;33:867–78.
   PubMed Web of Science ®Google Scholar
• Abdelsalam EA, Zaghary WA, Amin KM, et al. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors. Bioorg Chem 2019;89:102985.
   PubMed Web of Science ®Google Scholar
• Saleh NM, Abdel‐Rahman AAH, Omar AM, et al. Pyridine‐derived VEGFR‐2 inhibitors: rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking. Arch Pharm 2021;354:e2100085.
   PubMed Web of Science ®Google Scholar
• Martinez R, Chacon-Garcia L. The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work. Curr Med Chem 2005;12:127–51.
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Taghour M, Metwaly A, et al. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors. Eur J Med Chem 2018;155:117–34.
   PubMed Web of Science ®Google Scholar
• Eissa IH, El-Naggar AM, Abd El-Sattar NE, et al. Design and discovery of novel quinoxaline derivatives as dual DNA intercalators and topoisomerase II inhibitors. Anticancer Agents Med Chem 2018;18:195–209.
   PubMed Web of Science ®Google Scholar
• Eissa IH, Metwaly AM, Belal A, et al. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors. Arch Pharm 2019;352:1900123.
   PubMed Web of Science ®Google Scholar
• El-Helby A-GA, Sakr H, Ayyad RR, et al. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. Bioorg Chem 2020;103:104233.
   PubMed Web of Science ®Google Scholar
• Abbass EM, Khalil AK, Mohamed MM, et al. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers. Bioorg Chem 2020;104:104255.
   PubMed Web of Science ®Google Scholar
• El-Adl K, Ibrahim M-K, Alesawy MS, et al. [1, 2, 4] Triazolo [4, 3-c] quinazoline and bis ([1, 2, 4] triazolo)[4, 3-a: 4′, 3′-c] quinazoline derived DNA intercalators: design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies. Bioorg Medic Chem 2021;30:115958.
   PubMed Web of Science ®Google Scholar
• Alesawy MS, Al‐Karmalawy AA, Elkaeed EB, et al. Design and discovery of new 1, 2, 4‐triazolo [4, 3‐c] quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Archiv der Pharmazie 2020;354:e2000237.
   PubMed Web of Science ®Google Scholar
• Ferguson LR, Denny WA. Genotoxicity of non-covalent interactions: DNA intercalators. Mutat Res Fundamental Mol Mech Mutagen 2007;623:14–23.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009;16:3267–85.
   PubMed Web of Science ®Google Scholar
• Ghanem A, Emara HA, Muawia S, et al. Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K/AKT/mTOR pathway and inhibition of topoisomerase II: in vitro and molecular docking studies. N J Chem 2020;44:17374–81.
   Web of Science ®Google Scholar
• Kim JS, Rhee H-K, Park HJ, et al. Synthesis of 1-/2-substituted-[1,2,3]triazolo[4,5-g]phthalazine-4,9-diones and evaluation of their cytotoxicity and topoisomerase II inhibition. Bioorg Med Chem 2008;16:4545–50.
   PubMed Web of Science ®Google Scholar
• El-Shershaby MH, Ghiaty A, Bayoumi AH, et al. From triazolophthalazines to triazoloquinazolines: a bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity. Bioorg Med Chem 2021;42:116266.
   PubMed Web of Science ®Google Scholar
• Gaber M, El-Wakiel NA, El-Ghamry H, Fathalla SK. Synthesis, spectroscopic characterization, DNA interaction and biological activities of Mn (II), Co (II), Ni (II) and Cu (II) complexes with [(1H-1, 2, 4-triazole-3-ylimino) methyl] naphthalene-2-ol. J Mol Struc 2014;1076:251–61.
   Web of Science ®Google Scholar
• Chen C-Y, Lee P-H, Lin Y-Y, et al. Synthesis, DNA-binding abilities and anticancer activities of triazole-pyrrolo[2,1-c][1,4]benzodiazepines hybrid scaffolds. Bioorg Med Chem Lett 2013;23:6854–9.
   PubMed Web of Science ®Google Scholar
• El‐Helby AGA, Sakr H, Eissa IH, et al. Benzoxazole/benzothiazole‐derived VEGFR‐2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations. Archiv Der Pharmazie 2019;352:1900178.
   Web of Science ®Google Scholar
• El‐Helby AGA, Sakr H, Eissa IH, et al. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR‐2 inhibitors. Arch Pharm 2019;352:1900113.
   Web of Science ®Google Scholar
• Sakr H, Ayyad RR, El‐Helby AA, et al. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors. Arch Pharm 2021;354:e2000456.
   PubMed Web of Science ®Google Scholar
• Said MA, Eldehna WM, Nocentini A, et al. Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: design, synthesis, and in vitro biological evaluation. Eur J Med Chem 2020;189:112019.
   PubMed Web of Science ®Google Scholar
• Al-Sanea MM, Elkamhawy A, Paik S, et al. Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamidesAQ3 as carbonic anhydrase isoforms I and II inhibitors. J Enzyme Inhib Med Chem 2019;34:1457–64.
   PubMed Web of Science ®Google Scholar
• Avendaño C, Menendez JC, Medicinal chemistry of anticancer drugs. Elsevier, UK; 2015.
   Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185–229.
   PubMed Web of Science ®Google Scholar
• El-Helby AGA, Ayyad RR, Sakr HM, et al. Design, synthesis, molecular modeling and biological evaluation of novel 2, 3-dihydrophthalazine-1, 4-dione derivatives as potential anticonvulsant agents. J Mol Struct 2017;1130:333–51.
   Web of Science ®Google Scholar
• Xue D-Q, Zhang X-Y, Wang C-J, et al. Synthesis and anticancer activities of novel 1,2,4-triazolo[3,4-a]phthalazine derivatives . Eur J Medic Chem 2014;85:235–44.
   PubMed Web of Science ®Google Scholar
• El‐Helby AGA, Ayyad RR, Sakr H, et al. Design, synthesis, molecular docking, and anticancer activity of phthalazine derivatives as VEGFR‐2 inhibitors. Archiv Der Pharmazie 2017;350:1700240.
   Web of Science ®Google Scholar
• Badr M, El‐Sherief H, El‐Naggar G, Mahgoub S. Substitution and ring closure reactions of phthalazine derivatives. J. Heterocycl. Chem 1984;21:471–5.
   Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271–7.
   PubMed Web of Science ®Google Scholar
• Thabrew M, Hughes RD, Mcfarlane IG. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol 2011;49:1132–5.
   Web of Science ®Google Scholar
• Burres NS, Frigo A, Rasmussen RR, McAlpine JB. A colorimetric microassay for the detection of agents that interact with DNA. J Nat Prod 1992;55:1582–7.
   PubMed Web of Science ®Google Scholar
• Patra N, De U, Kang J-A, et al. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. Euro J Pharmacol 2011;658:98–107.
   PubMed Web of Science ®Google Scholar
• Nafie MS, Arafa K, Sedky NK, et al. Triaryl dicationic DNA minor-groove binders with antioxidant activity display cytotoxicity and induce apoptosis in breast cancer. Chem Biol Interact 2020;324:109087.
   PubMed Web of Science ®Google Scholar
• Dicato M, Plawny L, Diederich M. Anemia in cancer. Ann. Oncol 2010;21:vii167–vii172.
   PubMed Web of Science ®Google Scholar
• ElZahabi HS, Nafie MS, Osman D, et al. Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity. Euro J Med Chem 2021;222:113609.
   PubMed Web of Science ®Google Scholar
• Boraei AT, Eltamany EH, Ali IA, et al. Synthesis of new substituted pyridine derivatives as potent anti-liver cancer agents through apoptosis induction: in vitro, in vivo, and in silico integrated approaches. Bioorg Chem 2021;111:104877.
   PubMed Web of Science ®Google Scholar
• Xia X, Maliski EG, Gallant P, Rogers D. Classification of kinase inhibitors using a Bayesian model. J Med Chem 2004;47:4463–4470.
   PubMed Web of Science ®Google Scholar
• BIOVIA QSAR, ADMET and predictive toxicology. 2020. https://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio/qsar-admet-and-predictive-toxicology.html
   Google Scholar
• Carling RW, Moore KW, Street LJ, et al. 3-Phenyl-6-(2-pyridyl) methyloxy-1, 2, 4-triazolo [3, 4-a] phthalazines and analogues: high-affinity γ-aminobutyric acid-A benzodiazepine receptor ligands with α2, α3, and α5-subtype binding selectivity over α1. J Med Chem 2004;47:1807–1822.
   PubMed Web of Science ®Google Scholar
• Alswah M, Ghiaty A, El-Morsy A, El-Gamal K. Synthesis and biological evaluation of some [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as novel anticonvulsant agents. Inter Scholarly Res Notices 2013;2013:587054.
   Google Scholar
• El-Zahabi MA, Elbendary ER, Bamanie FH, et al. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPARγ and SUR agonists. Bioorganic Chemistry 2019;91:103115.
   PubMed Web of Science ®Google Scholar
• Ibrahim MK, Eissa IH, Alesawy MS, et al. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists. Bioorg Med Chem 2017;25:4723–4744.
   PubMed Web of Science ®Google Scholar
• Eissa IH, Dahab MA, Ibrahim MK, et al. Design and discovery of new antiproliferative 1,2,4-triazin-3(2H)-ones as tubulin polymerization inhibitors targeting colchicine binding site. Bioorg Chem. 2021;112:104965.
   PubMed Web of Science ®Google Scholar
• Parmar DR, Soni JY, Guduru R, et al. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Bioorg Chem 2021;115:105206.
   PubMed Web of Science ®Google Scholar
• El-Demerdash A, Metwaly AM, Hassan A, et al. Comprehensive virtual screening of the antiviral potentialities of marine polycyclic guanidine alkaloids against SARS-CoV-2 (COVID-19). Biomolecules 2021;11:460.
   PubMed Web of Science ®Google Scholar
• Eissa IH, Khalifa MM, Elkaeed EB, et al. In silico exploration of potential natural inhibitors against SARS-Cov-2 nsp10. Molecules 2021;26:6151.
   PubMed Web of Science ®Google Scholar